Mass Tort Lead Generation for Attorneys
Zantac lead generation for plaintiff firms
Pre-screened Zantac (ranitidine) NDMA exposure claimants with actively litigated cancer diagnoses, delivered to firms positioned in remaining viable venues.
Why this docket
Why Zantac matters right now
The federal MDL was dismissed under Daubert, but state-court Zantac litigation continues in Delaware, California, Illinois, and other venues — and several manufacturers have entered partial settlement frameworks. The docket favors firms with a sharp venue strategy and tight diagnosis-period screening. We deliver claimants pre-filtered against current viable venues and the specific cancer diagnoses still being litigated.
Our screening criteria
What we filter for before a lead reaches your intake
We screen against the public eligibility window for the Zantac docket plus any firm-specific retainer criteria you set. Leads that fail any criterion are flagged and routed out — not delivered to you.
- Documented Zantac (ranitidine) usage with duration and frequency
- Diagnosis of bladder, gastric, esophageal, liver, or pancreatic cancer (and case-by-case other NDMA-linked cancers)
- Usage timeline before manufacturer recall (April 2020)
- Residence in or filing eligibility for a viable state-court venue
- No prior representation or settlement on the same claim
What you get
Built for Zantac acquisition partners
Exclusive, not shared
Every lead is routed to one firm only. We don't sell the same claimant to three competing firms — your intake team won't be racing competitors for the signature.
Pre-screened to your criteria
Before any lead reaches your intake, we screen against the docket's eligibility window, exposure duration, diagnosis, and any firm-specific retainer requirements you set.
Live transfer or scheduled delivery
Hot leads transfer live to your intake line during business hours. Off-hours leads queue into your CRM with full intake notes for next-business-day follow-up.
Compliance-vetted creative
Every ad creative and landing page is reviewed against TCPA, state bar advertising rules, FTC, and platform-specific policies before campaigns go live.
Specific to the Zantac docket
- Usage-duration verification (prescription vs OTC, dates, frequency)
- Diagnosis confirmation collected at intake
- State-of-residence filtering against viable venue list
- Cancer-type categorization for case-value triage
- Prior-recall-period confirmation
- Live transfer or CRM-queued delivery
Pricing
How Zantac lead pricing works
Zantac pricing reflects the venue-narrow nature of the docket. Claimants filing in viable state-court venues with the strongest diagnoses (bladder, gastric) command higher prices; pancreatic, liver, esophageal cases price tier-two. Both cost-per-qualified-lead and cost-per-signed-retainer models are available.
Ready to source Zantac claimants?
Get a docket-fit review for your firm
15 minutes. No pitch deck. We walk through which campaigns make sense for your state, what pricing would look like for Zantac, and what we would avoid.
Ready to review your next mass tort campaign?
Tell us about your firm, target cases, and intake capacity. A strategist will respond within one business day with practical next steps.
Built for personal injury firms, intake teams, and mass tort dockets